You are here

Article Text

Article menu
Download PDFPDF
Haematology
Bupropion-induced pancytopenia
  1. Jowon L Kim1,
  2. David Chercover2,
  3. Hamid Masoudi2 and
  4. Lynda Foltz1
  1. 1Division of Hematology, The University of British Columbia, Vancouver, British Columbia, Canada
  2. 2Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada
  1. Correspondence to Dr Jowon L Kim; jowonlaura.kim{at}ubc.ca

Abstract

Bupropion is not a well established cause of medication-induced pancytopenia. In this report, we discuss a case of agranulocytosis, normocytic anemia and severe thrombocytopenia, with concurrent drug-induced rash within 3 weeks of bupropion initiation. Bone marrow biopsy demonstrated hypocellularity <10% without dysplastic features or increase in blast cells. Other causes of cytopenias, including infections, nutritional deficiencies, autoimmune disorders, liver/renal disease, thrombotic microangiopathy, primary bone marrow disorders and secondary marrow infiltrative diseases were ruled out. Pancytopenia resolved after 1 week of bupropion discontinuation and supportive care.

  • Haematology (drugs and medicines)
  • Safety
  • Unwanted effects / adverse reactions
  • Drugs: psychiatry
  • Mood disorders (including depression)

https://doi.org/10.1136/bcr-2024-262831

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors JLK and LF contributed to the case report’s conception, design, data collection, data analysis and writing of the paper. DC and HM provided pathology specimen photos and interpretation, and reviewed and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.